LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

ClinicalTrials.gov ID: NCT07288398

Public ClinicalTrials.gov record NCT07288398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction

Study identification

NCT ID: NCT07288398
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Enrollment: 540 participants

Conditions and interventions

Conditions

Pulmonary Hypertension Associated With HFpEF

Interventions

Placebo Drug
TNX-103 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2, 2026
Primary completion: Jun 29, 2028
Completion: Jun 29, 2029
Last update posted: Mar 15, 2026

2026 – 2029

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 18

Facility	City	State	ZIP	Site status
Tenax Investigational Site	Alexander City	Alabama	35010	Recruiting
Tenax Investigational Site	Tamarac	Florida	33321	Not yet recruiting
Tenax Investigational Site	Mount Prospect	Illinois	60056	Not yet recruiting
Tenax Investigational Site	Peoria	Illinois	61636	Recruiting
Tenax Investigational Site	New Orleans	Louisiana	70115-6969	Recruiting
Tenax Investigational Site	West Monroe	Louisiana	71291	Recruiting
Tenax Investigational Site	Ypsilanti	Michigan	48197	Not yet recruiting
Tenax Investigational Site	Reno	Nevada	89502	Recruiting
Tenax Investigational Site	New York	New York	10032	Not yet recruiting
Tenax Investigational Site	Winston-Salem	North Carolina	27101	Recruiting
Tenax Investigational Site	Allentown	Pennsylvania	18105	Not yet recruiting
Tenax Investigational Site	Wynnewood	Pennsylvania	19096-3450	Not yet recruiting
Tenax Investigational Site	Nashville	Tennessee	37205	Recruiting
Tenax Investigational Site	Austin	Texas	78705	Recruiting
Tenax Investigational Site	Dallas	Texas	75390	Recruiting
Tenax Investigational Site	Houston	Texas	77002	Recruiting
Tenax Investigational Site	Norfolk	Virginia	23507-1904	Not yet recruiting
Tenax Investigational Site	Marshfield	Wisconsin	54449	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07288398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 15, 2026 · Synced Apr 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07288398 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →